

**A. For Equity Issues**

Sr. No.	Name of the issue: Kwaliti Pharmaceuticals Limited				
1	Type of issue	Initial Public Offering (IPO) on SME Platform of BSE			
	source: Prospectus of the Company				
2	Issue size	Rs.621.00 Lakhs			
	Source: Prospectus of the Company				
3	Grade of issue alongwith name of the rating agency	Since the issue is being made in terms of Chapter XB of the SEBI (ICDR) Regulations, there is no requirement of appointing a IPO Grading agency.			
	Source: Prospectus of the Company				
4	Subscription level (number of times)	1.35			
	Source: Final post-issue report - Before Technical rejection				
5	QIB holding (as a % of total outstanding capital) as disclosed to stock exchanges (See Clause 37 of the SME listing agreement)				
	(i) allotment in the issue	NIL			
	(i) at the end of 1st FY (2016-17)	NIL			
	(ii) at the end of 2nd FY (2017-18)	Not Available			
	(iii) at the end of 3rd FY (2018-19)	Not Available			
	Source: BSE(SHP)				
6	Financials of the issuer (as per the annual financial results submitted to stock exchange under clause 43 of SME listing agreement)				
	(Rs. in lakhs)				
	Parameters	1st FY (2016-17)	2nd FY (2017-18)	3rd FY (2018-19)	
	Income from operations	9952.41	13829.65	Not Available	
	Net Profit for the period	336.39	454.61	Not Available	
	Paid-up equity share capital	518.81	1037.62	Not Available	
	Reserves excluding revaluation reserves	2039.6	1937.16	Not Available	
	Source: BSE				
7	Trading status in the scrip of the issuer (whether frequently traded (as defined under Regulation 2 (j) of SEBI (SAST) Regulations, 2011) or infrequently traded/ delisted/ suspended by any stock exchange, etc.)				
	(i) at the end of 1st FY (2016-17)	Frequently Traded			
	(ii) at the end of 2nd FY (2017-18)	Frequently Traded			
	(iii) at the end of 3rd FY (2018-19)	Not Available			
	Source: BSE				
8	Change, if any, in directors of issuer from the disclosures in the offer document (See Clause 32 of the SME listing agreement)				
	Particulars	Name of Director	Appointed/Resigned		
	(i) at the end of 1st FY (2016-17)	NO Change			
	(ii) at the end of 2nd FY (2017-18)	NO Change			
	(iii) at the end of 3rd FY (2018-19)	NA			
	Source: MCA				
9	Status of implementation of project/ commencement of commercial production (as submitted to stock exchanges under Clause 43(IV) (e) of the listing agreement)				
	(i) Details of Estimated Schedule of Implementation of Projects forming part of the Objects of the Issue as per Prospectus				
	(Rs. In Lacs)				
	Particulars	(i) as disclosed in the offer document	(ii) Actual implementation upto FY 2016-17	(iii) Reasons for delay in implementation, if	
	Modernisation of our Laboratory	43.00	43.00	NA	
	To meet the part of General Corporate	20.00	20.00		
	To meet the expenses of the Offer	18.00	0.85		
	<b>Total</b>	<b>81.00</b>	<b>63.85</b>		
10	Status of utilization of issue proceeds (as submitted to stock exchanges under Clauses 43, 45 and 46 of the listing agreement)				
	(i) As disclosed in the offer document (Rs. In Lakhs)				
	Particulars	(i) as disclosed in the offer document	(ii) Actual implementation		Total Fund unutilised
			Already incurred as on date of	Incurred upto F.Y 2016-17	
	Modernisation of our Laboratory	43.00	0.00	43.00	0.00
	General Corporate Purpose	20.00	0.00	20.00	0.00
	Offer Expenses	18.00	17.15	0.85	0.00
	<b>Total</b>	<b>81.00</b>	<b>17.15</b>	<b>63.85</b>	<b>0.00</b>
11	Comments of monitoring agency	Not Applicable as the issue size was less than Rs. 500 crores			

## 12 Price-related data

Issue price (Rs):	Rs. 35/-
-------------------	----------

Price parameters	At close of listing day (July 18, 2016)	At close of 30th calendar day (August 10, 2016) from listing day	At close of 90th calendar day from listing day (October 17, 2016)	As at the end of 1st FY after the listing of the issue (2016-17)		As at the end of 2nd FY after the listing of the issue (2017-18)			As at the end of 2nd FY after the listing of the issue (2018-19)		
				Closing price (March 06, 2017)	Low (during the FY) (July 21, 2016)	Closing price (March 28, 2018)	High (during the FY) (April 05, 2017)	Low (during the FY) (March 28, 2018)	Closing price	High (during the FY)	Low (during the FY)
Market Price (BSE)	44.50	45.05	51.80	96.00	40.85	41.00	103.15	41.00	N.A	N.A	N.A
Index (of the Designated Stock Exchange): BSE Sensex	27,746.66	27,774.88	27,529.97	29,048.19	27,687.54	32,968.68	30,007.48	32,917.66	N.A	N.A	N.A
Sectoral Index	N.A	N.A	N.A	N.A	N.A	N.A	N.A	N.A	N.A	N.A	N.A

Note: The Company belongs to the Pharmaceuticals Sector and there is no index for this particular Industry

Source: BSE

Note: 1. Where the 30th day / 90th day / March 31 of a particular year falls on a BSE trading holiday, the immediately following trading day has been considered.

2. Where the 30th day / 90th day / March 31 of a particular year falls on the day when there is no trade in equity share of the Company, preceding trading day has been considered.

## 13 Basis for Issue Price and Comparison with Peer Group &amp; Industry Average (Source of accounting ratios of peer group and industry average may be indicated; source of the accounting ratios may generally be the same, however in case of different sources, reasons for the same may be indicated)

Accounting ratio	Name of company	As disclosed in the offer document (See Clause (2) (VII) (K) of Schedule VIII to SEBI (ICDR) Regulations, 2009 as on March 2015	At the end of 1st FY (2016-17)#	At the end of 2nd FY (2017-18) #
EPS (Basic & before Extraordinary Items)	Issuer: Kwaliti Pharmaceuticals Limited	1.81	6.48	4.38
	Peer Group:			
	Albert David Limited	24.01	27.96	17.24
	Bliss GVS Pharma Limited	5.82	7.95	5.7
	Caplin Point Laboratories Limited	27.09	12.65	19.26
	Industry Avg:	28.46	24.28	21.10
P/E	Issuer: Kwaliti Pharmaceuticals Limited	24.86	14.81	9.36
	Peer Group:			
	Albert David Limited	13.31	11.40	21.14
	Bliss GVS Pharma Limited	15.51	22.19	34.27
	Caplin Point Laboratories Limited	36.51	30.68	29.75
	Industry Avg:	32.67	32.13	42.58
RoNW (%)#	Issuer: Kwaliti Pharmaceuticals Limited	4.86	13.15	15.28
	Peer Group:			
	Albert David Limited	14.76	7.94	3.61
	Bliss GVS Pharma Limited	16.30	21.86	16.29
	Caplin Point Laboratories Limited	42.36	42.60	39.96
	Industry Avg:	36.71	36.20	29.93
NAV per share based on balance sheet	Issuer: Kwaliti Pharmaceuticals Limited	37.29	49.31	28.67
	Peer Group:			
	Albert David Limited	162.80	320.67	325.81
	Bliss GVS Pharma Limited	35.70	471.77	519.88
	Caplin Point Laboratories Limited	63.95	148.56	240.62
	Industry Avg:	131.23	470.50	543.15

# Sourced from the Annual Report of the Company for the relevant fiscal year except for share price information which has been sourced from BSE website. Key ratios for the Company have been calculated on the basis of standalone financial information as follows: (i) EPS - Fully diluted EPS as reported by the Company in its Annual Report

(ii) P/E is computed based on the closing price of the shares of the Company as on the fiscal year end (on Bombay Stock Exchange) divided by the EPS for the year as reported in the annual report / company filings

(iii) Return on Net Worth = Net profit/(loss) after tax / Networth\*100; based on annual report / company filings of the Company

(iv) Net Asset Value per Equity Share = Networth / Number of equity shares outstanding at the end of the year; based on annual report / company filings of the Company

Note: Industry average has been calculated by taking the average of peer group companies.

## 14 Any other material information

Nil